Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study

Simple item page
dc.citation.issue18
dc.citation.volume16
dc.contributor.authorLasham A
dc.contributor.authorRamsaroop R
dc.contributor.authorWrigley A
dc.contributor.authorKnowlton N
dc.contributor.editorRadisky D
dc.contributor.editorLambertini M
dc.coverage.spatialSwitzerland
dc.date.accessioned2025-03-19T01:53:02Z
dc.date.available2025-03-19T01:53:02Z
dc.date.issued2024-09-20
dc.description.abstractOBJECTIVES: To perform the first national analysis of demographic and clinicopathological features associated with the HER2 positive, HER2-low, and HER2-zero invasive breast cancers in New Zealand. The study will reveal the proportion of women who may benefit from new HER2-targeted antibody drug conjugate (ADC) therapies. METHODS: Utilising data from Te Rēhita Mate Ūtaetae (Breast Cancer Foundation NZ National Register), the study analysed data from women diagnosed with invasive breast cancer over a 21-year period. The HER2 status of tumours was classified into three categories-HER2-zero, HER2-low, HER2-positive. RESULTS: From 2009-2021, 94% of women underwent HER2 testing, with 14% diagnosed with HER2-positive breast cancer. For advanced-stage disease, 38% of those formerly classified as HER2-negative were reclassified as HER2-low. Including HER2-positive breast cancers, this indicates that 60% of women with advanced breast cancer may potentially benefit from the new HER2-directed ADCs (approximately 120 women per year). CONCLUSIONS: The findings suggest a significant proportion of women with invasive breast cancer in New Zealand could benefit from new HER2-targeted treatments. There is a need to standardise HER2 testing to enhance personalised treatment and improve outcomes.
dc.description.confidentialfalse
dc.edition.editionSeptember-2 2024
dc.format.pagination3204-
dc.identifier.author-urlhttps://www.ncbi.nlm.nih.gov/pubmed/39335175
dc.identifier.citationLasham A, Ramsaroop R, Wrigley A, Knowlton N. (2024). Analysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study.. Cancers (Basel). 16. 18. (pp. 3204-).
dc.identifier.doi10.3390/cancers16183204
dc.identifier.eissn2072-6694
dc.identifier.elements-typejournal-article
dc.identifier.issn2072-6694
dc.identifier.number3204
dc.identifier.piicancers16183204
dc.identifier.urihttps://mro.massey.ac.nz/handle/10179/72679
dc.languageeng
dc.publisherMDPI (Basel, Switzerland)
dc.publisher.urihttps://www.mdpi.com/2072-6694/16/18/3204
dc.relation.isPartOfCancers (Basel)
dc.rights(c) 2024 The Author/s
dc.rightsCC BY 4.0
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subjectAotearoa New Zealand
dc.subjectHER2 testing
dc.subjectHER2-low breast cancer
dc.subjectantibody-drug conjugates (ADCs)
dc.subjectbreast cancer treatment
dc.subjectcancer diagnostics
dc.subjectclinical oncology
dc.subjectpersonalised medicine
dc.subjecttargeted therapy
dc.titleAnalysis of HER2-Low Breast Cancer in Aotearoa New Zealand: A Nationwide Retrospective Cohort Study
dc.typeJournal article
pubs.elements-id500077
pubs.organisational-groupOther
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
500077 PDF.pdf
Size:
1.2 MB
Format:
Adobe Portable Document Format
Description:
Evidence
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
9.22 KB
Format:
Plain Text
Description:
Download
Collections
Journal Articles